Angiogenesis in symptomatic intracranial atherosclerosis -: Predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence

被引:40
作者
Arenillas, JF
Alvarez-Sabín, J
Montaner, J
Rosell, A
Molina, CA
Rovira, A
Ribó, M
Sánchez, E
Quintana, M
机构
[1] Vall Hebron Univ Hosp, Neurovasc Unit, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Neurovasc Res Lab, Barcelona, Spain
[3] Vall Hebron Univ Hosp, Magnet Resonance Unit, Barcelona, Spain
关键词
angiogenesis; atherosclerosis; intracranial; endostatins; intracranial stenosis; vascular endothelial growth factor;
D O I
10.1161/01.STR.0000149617.65372.5d
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Angiogenesis may be beneficial in chronic myocardial and limb ischemia, but its role in intracranial atherosclerosis remains unknown. We aimed to investigate the relationship between the pro-angiogenic vascular endothelial growth factor (VEGF) and the anti-angiogenic endostatin, and the extent and risk of recurrence of symptomatic intracranial atherosclerosis. Methods-Of a total of 94 consecutive patients with symptomatic intracranial stenoses, 40 fulfilled all inclusion criteria. Intracranial stenoses were confirmed by magnetic resonance angiography. Magnetic resonance imaging (MRI) including diffusion-weighted sequences was conducted. Plasmatic VEGF and endostatin were determined from blood samples obtained 3 months after stroke onset, and patients were followed-up thereafter. Results-A total of 144 intracranial stenoses were confirmed (median number per patient=3). Endostatin/VEGF ratio gradually augmented with the increasing number of intracranial stenoses (r=0.35, P=0.02). Diabetes mellitus (OR, 6.04; CI, 1.1 to 32.2; P=0.03) and a higher endostatin/VEGF ratio (OR, 15.7; CI, 2.2 to 112.3; P=0.006) were independently associated with a greater extent of intracranial atherosclerosis. During a median follow-up of 13 months, 8 patients (20%) experienced a new cerebral ischemic event. A higher baseline endostatin concentration was an independent predictor of new events (hazard ratio, 7.24; CI, 1.6 to 33.8; P=0.011) in a Cox regression model after adjustment for age, sex, number of stenotic vessels, and risk factors. Patients with a higher endostatin level had a lower survival free of new events (P=0.01, log-rank test). Conclusions-A predominance of the inhibitor endostatin within the endogenous angiogenic response is associated with a greater extent and risk of recurrence of symptomatic intracranial atherosclerosis, suggesting that angiogenesis may be beneficial in this condition.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 24 条
[11]   ROLE OF ANGIOGENESIS IN PATIENTS WITH CEREBRAL ISCHEMIC STROKE [J].
KRUPINSKI, J ;
KALUZA, J ;
KUMAR, P ;
KUMAR, S ;
WANG, JM .
STROKE, 1994, 25 (09) :1794-1798
[12]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A SECRETED ANGIOGENIC MITOGEN [J].
LEUNG, DW ;
CACHIANES, G ;
KUANG, WJ ;
GOEDDEL, DV ;
FERRARA, N .
SCIENCE, 1989, 246 (4935) :1306-1309
[13]   NONINVASIVE DETECTION OF OCCLUSIVE DISEASE OF THE CAROTID SIPHON AND MIDDLE CEREBRAL-ARTERY [J].
LEYPOZO, J ;
RINGELSTEIN, EB .
ANNALS OF NEUROLOGY, 1990, 28 (05) :640-647
[14]   DOPPLER DIAGNOSIS OF INTRACRANIAL ARTERY OCCLUSIVE DISORDERS [J].
LINDEGAARD, KF ;
BAKKE, SJ ;
AASLID, R ;
NORNES, H .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1986, 49 (05) :510-518
[15]   Impairment of collateral formation in lipoprotein(a) transgenic mice - Therapeutic angiogenesis induced by human hepatocyte growth factor gene [J].
Morishita, R ;
Sakaki, M ;
Yamamoto, K ;
Iguchi, S ;
Aoki, M ;
Yamasaki, K ;
Matsumoto, K ;
Nakamura, T ;
Lawn, R ;
Ogihara, T ;
Kaneda, Y .
CIRCULATION, 2002, 105 (12) :1491-1496
[16]   Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice [J].
Moulton, KS ;
Heller, E ;
Konerding, MA ;
Flynn, E ;
Palinski, W ;
Folkman, J .
CIRCULATION, 1999, 99 (13) :1726-1732
[17]   Endostatin: An endogenous inhibitor of angiogenesis and tumor growth [J].
OReilly, MS ;
Boehm, T ;
Shing, Y ;
Fukai, N ;
Vasios, G ;
Lane, WS ;
Flynn, E ;
Birkhead, JR ;
Olsen, BR ;
Folkman, J .
CELL, 1997, 88 (02) :277-285
[18]   Angiogenesis in human cerebral ischemia [J].
Rosell-Novel, A ;
Montaner, J ;
Alvarez-Sabín, J .
REVISTA DE NEUROLOGIA, 2004, 38 (11) :1076-1082
[19]   Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease [J].
Rosengart, TK ;
Lee, LY ;
Patel, SR ;
Sanborn, TA ;
Parikh, M ;
Bergman, GW ;
Hachamovitch, R ;
Szulc, M ;
Kligfield, PD ;
Okin, PM ;
Hahn, RT ;
Devereux, RB ;
Post, MR ;
Hackett, NR ;
Foster, T ;
Grasso, TM ;
Lesser, ML ;
Isom, OW ;
Crystal, RG .
CIRCULATION, 1999, 100 (05) :468-474
[20]   Novel therapeutic strategy to treat brain ischemia - Overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model [J].
Shimamura, M ;
Sato, N ;
Oshima, K ;
Aoki, M ;
Kurinami, H ;
Waguri, S ;
Uchiyama, Y ;
Ogihara, T ;
Kaneda, Y ;
Morishita, R .
CIRCULATION, 2004, 109 (03) :424-431